{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T03:22:51Z","timestamp":1740108171695,"version":"3.37.3"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2020,9,23]],"date-time":"2020-09-23T00:00:00Z","timestamp":1600819200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,9,23]],"date-time":"2020-09-23T00:00:00Z","timestamp":1600819200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100005626","name":"Universit\u00e4t Regensburg","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100005626","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nervenarzt"],"published-print":{"date-parts":[[2021,5]]},"abstract":"<jats:title>Zusammenfassung<\/jats:title><jats:sec>\n                <jats:title>Hintergrund<\/jats:title>\n                <jats:p>Psychisch Kranke haben ein erh\u00f6htes kardiovaskul\u00e4res Mortalit\u00e4tsrisiko. Zur Prophylaxe und Therapie von Herz-Kreislauf-Erkrankungen werden insbesondere Antihypertensiva eingesetzt. In Kombination mit Psychopharmaka resultiert ein Interaktionspotenzial, wodurch das Erreichen therapeutischer Ziele beeintr\u00e4chtigt werden kann.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Ziel<\/jats:title>\n                <jats:p>Das Verordnungsverhalten bei Antihypertensiva in psychiatrischen Kliniken und Praxen im deutschsprachigen Raum sowie das Interaktionspotenzial mit Psychopharmaka soll untersucht werden.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methoden<\/jats:title>\n                <jats:p>Es erfolgte eine Auswertung der AGATE-\u201eStichtags\u201c-Datenbank, welche anonym die Patientendaten Alter, Geschlecht, psychiatrische Hauptdiagnose sowie die verordneten Handelspr\u00e4parate enth\u00e4lt. Die Auswertung der m\u00f6glichen Interaktionen erfolgte mit PSIAC.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Ergebnisse<\/jats:title>\n                <jats:p>Zwischen 01.01.2012 und 31.12.2016 wiesen 27\u202f% aller 21.980 erfassten Patienten eine Verordnung f\u00fcr mindestens ein Antihypertensivum auf, wobei der Anteil mit dem Alter auf 72\u202f% bei den \u00fcber 80-J\u00e4hrigen anstieg. 48\u202f% der antihypertensiv Behandelten erhielten eine blutdrucksenkende Monotherapie. Mit dem Alter stieg die Bedeutung der antihypertensiven Kombinationstherapie. Insgesamt wurden den Patienten im Median\u00a07 Wirkstoffe verordnet, wodurch mathematisch 21\u00a0Interaktionen resultieren. Durch eine gleichzeitige Gabe von Psychopharmaka und Blutdrucksenkern kann es vor allem zu einem erh\u00f6hten Risiko f\u00fcr Hypotonie, unzureichende Blutdrucksenkung oder QTc-Zeitverl\u00e4ngerung kommen.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Diskussion<\/jats:title>\n                <jats:p>Antihypertensiva haben einen hohen Stellenwert bei der Behandlung psychiatrischer Patienten. Eine Interaktionspr\u00fcfung sollte durchgef\u00fchrt werden, wenn die Pharmakotherapie erg\u00e4nzt oder ver\u00e4ndert werden soll. Allenfalls sollten Ma\u00dfnahmen zur Verbesserung der Arzneimitteltherapiesicherheit erwogen werden.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s00115-020-00996-9","type":"journal-article","created":{"date-parts":[[2020,9,28]],"date-time":"2020-09-28T09:02:50Z","timestamp":1601283770000},"page":"487-493","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Antihypertensiva in der Psychiatrie","Antihypertensive drugs in psychiatry"],"prefix":"10.1007","volume":"92","author":[{"given":"Katharina","family":"Endres","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ernst","family":"Schiller","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ekkehard","family":"Haen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,9,23]]},"reference":[{"key":"996_CR1","doi-asserted-by":"publisher","DOI":"10.1515\/hmbci-2017-0065","author":"O Abosi","year":"2018","unstructured":"Abosi\u00a0O, Lopes\u00a0S, Schmitz\u00a0S et\u00a0al (2018) Cardiometabolic effects of psychotropic medications. Horm Mol Biol Clin Investig. https:\/\/doi.org\/10.1515\/hmbci-2017-0065","journal-title":"Horm Mol Biol Clin Investig"},{"issue":"16","key":"996_CR2","doi-asserted-by":"publisher","first-page":"1471","DOI":"10.2146\/ajhp080238","volume":"66","author":"JS Benner","year":"2009","unstructured":"Benner\u00a0JS, Chapman\u00a0RH, Petrilla\u00a0AA et al (2009) Association between prescription burden and medication adherence in patients initiating antihypertensive and lipid-lowering therapy. Am J Health Syst Pharm 66(16):1471\u20131477","journal-title":"Am J Health Syst Pharm"},{"issue":"12","key":"996_CR3","first-page":"814","volume":"53","author":"O-E Brodde","year":"2003","unstructured":"Brodde\u00a0O\u2011E, Kroemer\u00a0HK (2003) Drug-drug interactions of beta-adrenoceptor blockers. Arzneimittelforschung 53(12):814\u2013822","journal-title":"Arzneimittelforschung"},{"issue":"4","key":"996_CR4","doi-asserted-by":"publisher","first-page":"e444","DOI":"10.4088\/JCP.14m09469","volume":"77","author":"JR Cougle","year":"2016","unstructured":"Cougle\u00a0JR, Hakes\u00a0JK, Macatee\u00a0RJ et\u00a0al (2016) Probability and correlates of dependence among regular users of alcohol, nicotine, cannabis, and cocaine. Concurrent and prospective analyses of the National Epidemiologic Survey on Alcohol and Related Conditions. J\u00a0Clin Psychiatry 77(4):e444\u2013e450","journal-title":"J Clin Psychiatry"},{"issue":"16","key":"996_CR5","doi-asserted-by":"publisher","first-page":"e100","DOI":"10.1055\/s-0043-111739","volume":"142","author":"RW Freudenmann","year":"2017","unstructured":"Freudenmann\u00a0RW, Freudenmann\u00a0N, Zurowski\u00a0B et al (2017) Arterielle Hyper- und Hypotonie assoziiert mit Psychopharmaka. Eine Risikobewertung basierend auf den Fachinformationen (Arterial Hyper- and Hypotension associated with psychiatric medications: a\u00a0risk assessment based on the summaries of product characteristics (SmPCs)). Dtsch Med Wochenschr 142(16):e100\u2013e107","journal-title":"Dtsch Med Wochenschr"},{"issue":"1","key":"996_CR6","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1111\/imj.12319","volume":"44","author":"EL Gladigau","year":"2014","unstructured":"Gladigau\u00a0EL, Fazio\u00a0TN, Hannam\u00a0JP et\u00a0al (2014) Increased cardiovascular risk in patients with severe mental illness. Intern Med\u00a0J 44(1):65\u201369","journal-title":"Intern Med J"},{"issue":"4","key":"996_CR7","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1007\/s00115-013-3935-0","volume":"85","author":"E Haen","year":"2014","unstructured":"Haen\u00a0E (2014) Arzneimittelinteraktionen. Interaktionen zwischen korperfremden Substanzen (Drug-drug interactions: interactions between xenobiotics). Nervenarzt 85(4):417\u2013426","journal-title":"Nervenarzt"},{"issue":"6","key":"996_CR8","first-page":"238","volume":"18","author":"E Haen","year":"2011","unstructured":"Haen\u00a0E, Laux\u00a0G (2011) Arzneimitteltherapiesicherheit \/ Pharmakovigilanz in der klinischen Psychopharmakotherapie. Das Kliniknetzwerk AGATE. Psychopharmakotherapie 18(6):238\u2013243","journal-title":"Psychopharmakotherapie"},{"issue":"3","key":"996_CR9","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1007\/s00115-017-0385-0","volume":"89","author":"M Hahn","year":"2018","unstructured":"Hahn\u00a0M, Roll\u00a0SC (2018) Validierung von Interaktionsdatenbanken in der Psychopharmakotherapie (Validation of interaction databases in psychopharmacotherapy). Nervenarzt 89(3):319\u2013326","journal-title":"Nervenarzt"},{"key":"996_CR10","unstructured":"Hiemke C, Eckermann G, Haen E, Dobmeier M et al. PSIAC. Springer, Heidelberg. www.psiac.de. Zugegriffen:  29.04.2020"},{"issue":"38","key":"996_CR11","doi-asserted-by":"publisher","first-page":"2893","DOI":"10.1093\/eurheartj\/ehw210","volume":"37","author":"P Kirchhof","year":"2016","unstructured":"Kirchhof\u00a0P, Benussi\u00a0S, Kotecha\u00a0D et\u00a0al (2016) 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur Heart\u00a0J 37(38):2893\u20132962","journal-title":"Eur Heart J"},{"issue":"5-6","key":"996_CR12","doi-asserted-by":"publisher","first-page":"868","DOI":"10.1007\/s00103-013-1667-8","volume":"56","author":"H Knopf","year":"2013","unstructured":"Knopf\u00a0H, Grams\u00a0D (2013) Arzneimittelanwendung von Erwachsenen in Deutschland. Ergebnisse der Studie zur Gesundheit Erwachsener in Deutschland (DEGS1) (Medication use of adults in Germany: results of the German Health Interview and Examination Survey for Adults (DEGS1)). Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz 56(5-6):868\u2013877","journal-title":"Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz"},{"key":"996_CR13","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehz425","author":"J Knuuti","year":"2019","unstructured":"Knuuti\u00a0J, Wijns\u00a0W, Saraste\u00a0A et\u00a0al (2019) 2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes. Eur Heart\u00a0J. https:\/\/doi.org\/10.1093\/eurheartj\/ehz425","journal-title":"Eur Heart J"},{"issue":"4","key":"996_CR14","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1055\/s-2006-944295","volume":"75","author":"J Kornischka","year":"2007","unstructured":"Kornischka\u00a0J, Cordes\u00a0J, Agelink\u00a0MW (2007) 40\u00a0Jahre Beta-Blocker in der Psychiatrie (40\u00a0years beta-adrenoceptor blockers in psychiatry). Fortschr Neurol Psychiatr 75(4):199\u2013210","journal-title":"Fortschr Neurol Psychiatr"},{"issue":"12","key":"996_CR15","doi-asserted-by":"publisher","first-page":"752","DOI":"10.1177\/070674371005501202","volume":"55","author":"D Lawrence","year":"2010","unstructured":"Lawrence\u00a0D, Kisely\u00a0S, Pais\u00a0J (2010) The epidemiology of excess mortality in people with mental illness. Can J Psychiatry 55(12):752\u2013760","journal-title":"Can J Psychiatry"},{"issue":"12","key":"996_CR16","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1177\/070674371506001208","volume":"60","author":"A Lesage","year":"2015","unstructured":"Lesage\u00a0A, Rochette\u00a0L, \u00c9mond\u00a0V et\u00a0al (2015) A surveillance system to monitor excess mortality of people with mental illness in Canada. Can J Psychiatry 60(12):571\u2013579","journal-title":"Can J Psychiatry"},{"key":"996_CR17","volume-title":"S3-Leitlinie Screening, Diagnose und Behandlung alkoholbezogener St\u00f6rungen","year":"2015","unstructured":"Mann\u00a0K, Hoch\u00a0E, Batra\u00a0A (Hrsg) (2015) S3-Leitlinie Screening, Diagnose und Behandlung alkoholbezogener St\u00f6rungen, 1.\u00a0Aufl. Springer, Berlin Heidelberg","edition":"1"},{"key":"996_CR18","doi-asserted-by":"publisher","first-page":"145","DOI":"10.3389\/fpsyt.2016.00145","volume":"7","author":"N Parletta","year":"2016","unstructured":"Parletta\u00a0N, Aljeesh\u00a0Y, Baune\u00a0BT (2016) Health behaviors, knowledge, life satisfaction, and wellbeing in people with mental illness across four countries and comparisons with normative sample. Front Psychiatry 7:145","journal-title":"Front Psychiatry"},{"issue":"29","key":"996_CR19","doi-asserted-by":"publisher","first-page":"2315","DOI":"10.1093\/eurheartj\/ehw106","volume":"37","author":"MF Piepoli","year":"2016","unstructured":"Piepoli\u00a0MF, Hoes\u00a0AW, Agewall\u00a0S et\u00a0al (2016) 2016 European Guidelines on cardiovascular disease prevention in clinical practice: The Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts)Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR). Eur Heart\u00a0J 37(29):2315\u20132381","journal-title":"Eur Heart J"},{"issue":"27","key":"996_CR20","doi-asserted-by":"publisher","first-page":"2129","DOI":"10.1093\/eurheartj\/ehw128","volume":"37","author":"P Ponikowski","year":"2016","unstructured":"Ponikowski\u00a0P, Voors\u00a0AA, Anker\u00a0SD et\u00a0al (2016) 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC)Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart\u00a0J 37(27):2129\u20132200","journal-title":"Eur Heart J"},{"volume-title":"Arzneiverordnungs-Report 2013. Aktuelle Daten, Kosten, Trends und Kommentare","year":"2013","key":"996_CR21","unstructured":"Schwabe\u00a0U, Paffrath\u00a0D (Hrsg) (2013) Arzneiverordnungs-Report 2013. Aktuelle Daten, Kosten, Trends und Kommentare. Springer, Berlin"},{"volume-title":"Arzneiverordnungs-Report 2014. Aktuelle Daten, Kosten, Trends und Kommentare","year":"2014","key":"996_CR22","unstructured":"Schwabe\u00a0U, Paffrath\u00a0D (Hrsg) (2014) Arzneiverordnungs-Report 2014. Aktuelle Daten, Kosten, Trends und Kommentare. Springer, Berlin Heidelberg"},{"volume-title":"Arzneiverordnungs-Report 2015. Aktuelle Daten, Kosten, Trends und Kommentare","year":"2015","key":"996_CR23","unstructured":"Schwabe\u00a0U, Paffrath\u00a0D (Hrsg) (2015) Arzneiverordnungs-Report 2015. Aktuelle Daten, Kosten, Trends und Kommentare. Springer, Berlin"},{"volume-title":"Arzneiverordnungs-Report 2016. Aktuelle Daten, Kosten, Trends und Kommentare","year":"2016","key":"996_CR24","unstructured":"Schwabe\u00a0U, Paffrath\u00a0D (Hrsg) (2016) Arzneiverordnungs-Report 2016. Aktuelle Daten, Kosten, Trends und Kommentare. Springer, Berlin, Heidelberg"},{"volume-title":"Arzneiverordnungs-Report 2017. Aktuelle Daten, Kosten, Trends und Kommentare","year":"2017","key":"996_CR25","unstructured":"Schwabe\u00a0U, Paffrath\u00a0D, Ludwig\u00a0W\u2011D et al (Hrsg) (2017) Arzneiverordnungs-Report 2017. Aktuelle Daten, Kosten, Trends und Kommentare. Springer, Berlin, Heidelberg"},{"issue":"3","key":"996_CR26","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1111\/eip.12251","volume":"10","author":"C Tek","year":"2016","unstructured":"Tek\u00a0C, Kucukgoncu\u00a0S, Guloksuz\u00a0S et al (2016) Antipsychotic-induced weight gain in first-episode psychosis patients. A meta-analysis of differential effects of antipsychotic medications. Early Interv Psychiatry 10(3):193\u2013202","journal-title":"Early Interv Psychiatry"},{"issue":"3","key":"996_CR27","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1002\/wps.20458","volume":"16","author":"D Vancampfort","year":"2017","unstructured":"Vancampfort\u00a0D, Firth\u00a0J, Schuch\u00a0FB et al (2017) Sedentary behavior and physical activity levels in people with schizophrenia, bipolar disorder and major depressive disorder. A global systematic review and meta-analysis. World Psychiatry 16(3):308\u2013315","journal-title":"World Psychiatry"},{"issue":"4","key":"996_CR28","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1001\/jamapsychiatry.2014.2502","volume":"72","author":"ER Walker","year":"2015","unstructured":"Walker\u00a0ER, McGee\u00a0RE, Druss\u00a0BG (2015) Mortality in mental disorders and global disease burden implications. A systematic review and meta-analysis. JAMA Psychiatry 72(4):334\u2013341","journal-title":"JAMA Psychiatry"},{"issue":"4","key":"996_CR29","first-page":"148","volume":"20","author":"K Wenzel-Seifert","year":"2013","unstructured":"Wenzel-Seifert\u00a0K, Ostermeier\u00a0C\u2011P, Omar\u00a0BN et al (2013) Unerw\u00fcnschte kardiovaskul\u00e4re Wirkungen von Pyschopharmaka. Pathophysiologie und Risikominimierung. Psychopharmakotherapie 20(4):148\u2013157","journal-title":"Psychopharmakotherapie"},{"issue":"10","key":"996_CR30","doi-asserted-by":"publisher","first-page":"1953","DOI":"10.1097\/HJH.0000000000001940","volume":"36","author":"B Williams","year":"2018","unstructured":"Williams\u00a0B, Mancia\u00a0G, Spiering\u00a0W et\u00a0al (2018) 2018 ESC\/ESH Guidelines for the management of arterial hypertension. The Task Force for the management of arterial hypertension of the European Society of Cardiology and the European Society of Hypertension: The Task Force for the management of arterial hypertension of the European Society of Cardiology and the European Society of Hypertension. J\u00a0Hypertens 36(10):1953\u20132041","journal-title":"J Hypertens"}],"container-title":["Der Nervenarzt"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00115-020-00996-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00115-020-00996-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00115-020-00996-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,23]],"date-time":"2021-09-23T00:40:21Z","timestamp":1632357621000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00115-020-00996-9"}},"subtitle":["Verordnungsverhalten und Interaktionspotenzial","Prescription behavior and potential drug-drug interactions"],"short-title":[],"issued":{"date-parts":[[2020,9,23]]},"references-count":30,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2021,5]]}},"alternative-id":["996"],"URL":"https:\/\/doi.org\/10.1007\/s00115-020-00996-9","relation":{},"ISSN":["0028-2804","1433-0407"],"issn-type":[{"type":"print","value":"0028-2804"},{"type":"electronic","value":"1433-0407"}],"subject":[],"published":{"date-parts":[[2020,9,23]]},"assertion":[{"value":"23 September 2020","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"K.\u00a0Endres, E.\u00a0Schiller und E.\u00a0Haen geben an, dass kein Interessenkonflikt besteht.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"F\u00fcr diesen Beitrag wurden von den Autoren keine Studien an Menschen oder Tieren durchgef\u00fchrt. F\u00fcr die aufgef\u00fchrten Studien gelten die jeweils dort angegebenen ethischen Richtlinien.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}}]}}